| Recruiting | Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) T-cell Lymphomas | Phase 1 / Phase 2 | 2026-04-15 |
| Not Yet Recruiting | A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15) Lymphoma, Non-Hodgkin | Phase 1 | 2026-03-01 |
| Recruiting | A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 / Phase 2 | 2026-01-29 |
| Recruiting | A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11) Immune Thrombocytopenia (ITP) | Phase 2 | 2026-01-15 |
| Recruiting | DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | 2025-08-19 |
| Recruiting | DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHA Non Small Cell Lung Cancer | Phase 1 / Phase 2 | 2025-07-16 |
| Recruiting | A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Non Small Cell Lung Cancer | Phase 1 | 2025-05-13 |
| Recruiting | Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2) Nonsmall-cell Lung Cancer | Phase 1 | 2024-06-12 |
| Recruiting | A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) Peripheral T-cell Lymphoma | Phase 3 | 2024-05-13 |
| Recruiting | DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | 2024-04-29 |
| Active Not Recruiting | DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) Diffuse Large B Cell Lymphoma | Phase 2 | 2024-03-13 |
| Completed | DZD9008 PK Study in Hepatic Impairment Subjects Hepatic Impairment | Phase 1 | 2023-10-17 |
| Completed | Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp Non-small Cell Lung Cancer | Phase 1 | 2023-07-31 |
| Recruiting | A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients W Non-small Cell Lung Cancer | Phase 2 | 2023-06-01 |
| Recruiting | DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Lymphoma, Non-Hodgkin | Phase 1 | 2023-05-15 |
| Recruiting | DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (W Non-small Cell Lung Cancer | Phase 2 | 2023-02-15 |
| Active Not Recruiting | A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell L Non-small Cell Lung Cancer | Phase 3 | 2022-12-13 |
| Completed | Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine Healthy Subjects | Phase 1 | 2022-07-27 |
| Completed | A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1) Lymphoma, Non-Hodgkin | Phase 1 / Phase 2 | 2022-06-01 |
| Completed | AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) Peripheral T Cell Lymphoma | Phase 2 | 2022-05-31 |
| Completed | AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) Peripheral T-cell Lymphoma | Phase 2 | 2022-03-17 |
| Completed | Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine Healthy Subjects | Phase 1 | 2022-01-25 |
| Completed | Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male Subjects Healthy Volunteers | Phase 1 | 2021-09-24 |
| Withdrawn | Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma ( Non-Hodgkin's B-cell Lymphoma | Phase 1 / Phase 2 | 2021-08-01 |
| Active Not Recruiting | Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6) Non-Small Cell Lung Cancer | Phase 2 | 2021-07-19 |
| Completed | A Study of DZD2269 in Healthy Adult Participants Healthy Volunteers | Phase 1 | 2021-06-29 |
| Completed | Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of Healthy Volunteers | Phase 1 | 2021-04-21 |
| Terminated | Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC Metastatic Castration Resistant Prostate Cancer | Phase 1 | 2021-04-12 |
| Completed | DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metas Breast Cancer Metastatic | Phase 1 | 2020-09-21 |
| Completed | Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male Volunteers Healthy Volunteers | Phase 1 | 2020-01-06 |
| Completed | Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) Relapsed or Refractory Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | 2019-09-10 |
| Active Not Recruiting | Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | 2019-07-09 |
| Completed | A Study of AZD4205 in Healthy Adult Subjects Healthy Volunteers | Phase 1 | 2018-11-12 |
| Completed | Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanc Nonsmall Cell Lung Cancer | Phase 1 / Phase 2 | 2018-04-16 |